talimogene laherparepvec
Sign in to saveAlso known as T-Vec
modified herpes virus used for treatment of melanoma
In the Vinony graph
Vinony's link graph records 288 inbound references to talimogene laherparepvec, and connects out to oncolytic virus, tiazofurin and International Standard Book Number.
It sits within the topics Antineoplastic drugs, Approved gene therapies and Biotechnology.
Vinony links it to 7 Wikipedia language editions.
Medication
- Generic name
- Talimogene Laherparepvec
- Brand names
- Imlygic
- Drug class
- Antineoplastic cell and gene therapy
- Active ingredients
- herpesvirus 1, human
- Route
- Intralesional
- Dosage form
- Injection
- Type
- Human Prescription Drug
- Manufacturer
- Amgen Inc
Indications: 1 INDICATIONS AND USAGE IMLYGIC is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. Limitations of use : IMLYGIC has not been shown to improve over… (per FDA label)
Sources: openFDA · RxNorm (NLM). Not medical advice.
Research
449 papers- Talimogene Laherparepvec in Non-Melanoma Cancers.The Journal of clinical and aesthetic dermatology · 2021
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015
- Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class.Frontiers in molecular biosciences · 2022
- Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.Journal for immunotherapy of cancer · 2019
- Talimogene laherparepvec (T-VEC) and Emerging Intralesional Immunotherapies for Metastatic Melanoma: A Review.Current oncology reports · 2024
via PubMed
Clinical Trials
52 registered- EARLY_PHASE1COMPLETEDCombination of Talimogene Laherparepvec With Atezolizumab in Early Breast CancerSOLTI Breast Cancer Research Group · NCT03802604
- PHASE2COMPLETEDStudy of TVEC in Patients With Cutaneous Squamous Cell CancerUniversity of Arizona · NCT03714828
- PHASE1/PHASE2COMPLETEDTITAN (Tumoural Injection of T-VEC and Isolated Limb Perfusion)Royal Marsden NHS Foundation Trust · NCT03555032
- PHASE2TERMINATEDTalimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by SurgeryM.D. Anderson Cancer Center · NCT02658812
- COMPLETEDRegistry Study for Talimogene LaherparepvecAmgen · NCT02173171
- PHASE1TERMINATEDTalimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the SkinRutgers, The State University of New Jersey · NCT04163952
Wikidata facts
- Instance of
- medication
- Subclass of
- virus
- Image
- Herpes simplex virus TEM B82-0474 lores.jpg
Show 2 more facts
- World Health Organisation international non-proprietary name
- talimogene laherparepvec
- medical condition treated
- melanoma
Sources (2)
via Wikidata · CC0
Connections
oncolytic virus
Entity
tiazofurin
Entity
International Standard Book Number
Entity
common cold
Entity
Wayback Machine
Entity
anemia
Entity
digital object identifier
Entity
genetic engineering
Entity
chemotherapy
Entity
edema
Entity
vitiligo
Entity
melanoma
Entity
PubMed
Entity
DNA replication
Entity
University College London
Entity
hydrazine
Entity
cell cycle
Entity
DL-asparagine
Entity
CAS Registry Number
Entity
tachycardia
Entity